Heptares, Juntendo enter research and drug discovery collaboration
Tuesday, September 5, 2017
The new collaboration, Heptares’ fourth ORBIT program, is with the research group of Professor Takehiko Yokomizo, an expert on Molecular Biology, Immunology and Cell Biology and Professor of Department of Molecular and Cellular Biochemistry at Juntendo University. The collaboration is the first international industrial partnership for this prestigious university. Research activities will focus on the bespoke design and profiling of novel leukotriene receptor modulators with potential therapeutic utility in intractable skin/intestinal ulcers.
Fiona Marshall, Chief Scientific Officer of Heptares, said: “We are delighted to collaborate with Professor Yokomizo and his group at Juntendo University. Their extensive experience and knowledge of leukotriene receptors, combined with our own structure-based design expertise, forms a strong basis from which to generate novel selective, small molecules with the potential to address difficult-to-treat wounds. We look forward to a productive relationship.”
Prof. Yokomizo, Juntendo University, added: “Heptares has a strong global reputation based on its GPCR drug design capabilities. We are excited to collaborate on this new project, which has the potential to significantly advance our knowledge of the links between leukotriene receptor and disease, and to progress new drug design strategies in this area.”
Further information about ORBIT
ORBIT (Opportunities in Receptor Biology for Industrial Translation) is a collaborative research initiative launched by Heptares in February 2016 and designed to promote and broaden the application of its proprietary structure-based drug design expertise directed at GPCRs to create transformative medicines. Heptares is committing up to GBP 5 million over the next three years to fund this new initiative.
ORBIT will see Heptares collaborate with leading academic groups and emerging biotechnology companies. ORBIT aims to leverage the expertise of collaborators to seek out new links between GPCRs and diseases and develop a better understanding of disease biology relating to a broad range of GPCR targets. In parallel, Heptares will apply its world-leading GPCR-targeted drug discovery and translational medicine capabilities to generate a new wave of novel small molecules and biologics for advancement through its development pipeline.
Since its launch in February 2016, Heptares has initiated four ORBIT programmes focused on novel GPCR targets across multiple disease areas: with Imperial College London’s National Heart and Lung Institute (immune disorders), the University of Cambridge (cardiovascular diseases), New York University School of Medicine (glioblastoma multiforme) and Juntendo University (intractable skin/intestinal ulcers).